Athira Pharma Inc (ATHA) - Total Assets
Based on the latest financial reports, Athira Pharma Inc (ATHA) holds total assets worth $92.15 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See ATHA net asset quality score to measure how much of total assets are equity-financed.
Athira Pharma Inc - Total Assets Trend (2018–2025)
This chart illustrates how Athira Pharma Inc's total assets have evolved over time, based on quarterly financial data. Explore ATHA strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Athira Pharma Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Athira Pharma Inc's total assets of $92.15 Million consist of 97.1% current assets and 2.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 75.2% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Athira Pharma Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Athira Pharma Inc (ATHA) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Athira Pharma Inc's current assets represent 97.1% of total assets in 2025, a decrease from 99.3% in 2018.
- Cash Position: Cash and equivalents constituted 75.2% of total assets in 2025, up from 67.2% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Athira Pharma Inc Competitors by Total Assets
Key competitors of Athira Pharma Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Athira Pharma Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.88 | 4.18 | 69.28 |
| Quick Ratio | 1.88 | 4.18 | 69.28 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $41.95 Million | $41.71 Million | $307.07 Million |
Athira Pharma Inc - Advanced Valuation Insights
This section examines the relationship between Athira Pharma Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.67 |
| Latest Market Cap to Assets Ratio | 0.29 |
| Asset Growth Rate (YoY) | 56.8% |
| Total Assets | $92.15 Million |
| Market Capitalization | $26.62 Million USD |
Valuation Analysis
Below Book Valuation: The market values Athira Pharma Inc's assets below their book value (0.29x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Athira Pharma Inc's assets grew by 56.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Athira Pharma Inc (2018–2025)
The table below shows the annual total assets of Athira Pharma Inc from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $92.15 Million | +56.78% |
| 2024-12-31 | $58.78 Million | -63.32% |
| 2023-12-31 | $160.25 Million | -37.93% |
| 2022-12-31 | $258.15 Million | -22.24% |
| 2021-12-31 | $332.01 Million | +18.76% |
| 2020-12-31 | $279.56 Million | +12671.27% |
| 2019-12-31 | $2.19 Million | -55.63% |
| 2018-12-31 | $4.93 Million | -- |
About Athira Pharma Inc
Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds… Read more